Patents by Inventor Andrew Darrow

Andrew Darrow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6458564
    Abstract: Here we describe the molecular identification of a cDNA encoding a novel serine protease we have termed protease T. The deduced amino acid sequence encodes a prepro form of 290 amino acids, and its alignment with other well-characterized serine proteases indicates that it is a member of the S1 serine protease family. We have found that the protease T mRNA is expressed in stomach, testis, retina, fibroblasts, spinal cord, and several regions of the brain. Protease T MRNA is also found in leukocytes and in the Jurkat (ATCC TIB-152) T cell line. Thus, this protease is potentially involved in gastric, testicular, retinal, dematological, neurological/neurodegenerative and/or immunological disorders. The protease T gene maps to human chromosome 16p13.3 which is near the tryptase locus. Enzymatically active protease T, we have generated, is amenable to further biochemical analyses for the identification of physiological substrates and specific modulators.
    Type: Grant
    Filed: August 31, 1999
    Date of Patent: October 1, 2002
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Andrew Darrow, Jenson Qi, Patricia Andrade-Grodon
  • Publication number: 20020110895
    Abstract: Here we describe the molecular identification of a cDNA encoding a novel serine protease we have termed protease EOS. The deduced amino acid sequence, and it alignment with other well-characterized serine proteases indicates that it is a member of the S1 serine protease family. We have found that the protease EOS mRNA is expressed in platelets and leukocytes and more specifically eosinophils. Although this protease is abundantly expressed in ovary, retina and stomach, where it may perform important functions, its expression in platelets and certain cells of the immune system suggests that it may play roles in thrombosis and in the immune process. Enzymatically active protease EOS is amenable to further biochemical analyses for the identification of physiological substrates and specific modulators.
    Type: Application
    Filed: January 8, 2002
    Publication date: August 15, 2002
    Inventors: Andrew Darrow, Jenson Qi, Patricia Andrade-Gordon
  • DNA
    Patent number: 6426199
    Abstract: Here we describe the molecular identification of a cDNA encoding a novel serine protease we have termed protease C-E. The deduced amino acid sequence, and it alignment with other well-characterized serine proteases indicates that it is a member of the S1 serine protease family. We have found that the protease C-E mRNA is expressed in pancreas, placenta, prostate, small intestine, stomach, spleen, fibroblasts and epidermis, as well as in certain regions of the brain i.e., cerebellum, cerebral cortex, pituitary and hippocampus. Enzymatically active protease C-E, as produced using the methodologies described herein, is amenable to further biochemical analyses for the identification of physiological substrates and specific modulators.
    Type: Grant
    Filed: August 31, 1999
    Date of Patent: July 30, 2002
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Andrew Darrow, Jenson Qi, Patricia Andrade-Grodon
  • Patent number: 6420157
    Abstract: We describe the DNA sequences encoding an expression vector system that will permit, through limited proteolysis, the activation of expressed zymogen precursor of (S1) serine proteases in a highly controlled and reproducible fashion. The processed expressed protein, once activated, is rendered in a form amenable to measuring the catalytic activity. This catalytic activity of the activated form, is often a more accurate representation of the mature S1 protease gene product relative to the unprocessed zymogen precursor. Thus, this series of zymogen activation constructs represents a significant system for the analysis and characterization of serine protease gene products.
    Type: Grant
    Filed: August 31, 1999
    Date of Patent: July 16, 2002
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Andrew Darrow, Jenson Qi, Patricia Andrade-Grodon
  • Patent number: 6077990
    Abstract: Transgenic mice with a non-functional proteinase activated receptor-2 (PAR2) gene are prepared by targeted disruption of the endogenous PAR2 gene. The resulting transgenic mice display a phenotype including a lack of a hypotensive response to administration of the peptide, SLIGRL, and a reduction in carrageenin-induced paw edema compared to wild type mice.
    Type: Grant
    Filed: August 11, 1998
    Date of Patent: June 20, 2000
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Wai-Ping Leung, Andrew Darrow, Patricia Andrade-Gordon